SMS Pharmaceuticals Ltd Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Consolidate Quarterly Results

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Net Sales

242.43

196.05

248.20

173.35

196.75

164.45

245.80

Other Operating Income

0.00

Total Operating income

242.43

196.05

248.20

173.35

196.75

164.45

245.80

Raw Material Cost

106.56

146.66

117.54

118.32

158.77

107.24

97.47

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

33.26

-35.69

30.37

-32.83

-43.08

-19.28

63.22

Employee Cost

19.25

18.18

26.63

18.64

17.93

16.88

20.12

Power Cost

0.00

Manufacturing Expenses

25.74

19.73

25.41

20.75

22.00

18.20

21.86

Selling and Distribution Expenses

0.00

Other Expenses

9.26

7.80

7.44

15.26

9.66

7.90

9.51

Total Expenditure (Excl Depreciation)

194.07

156.68

207.39

140.14

165.28

130.94

212.18

Operating Profit (PBDIT) excl Other Income

48.36

39.37

40.81

33.21

31.47

33.51

33.62

Other Income

1.43

0.59

1.42

2.13

1.30

1.37

1.65

Operating Profit (PBDIT)

49.79

39.96

42.23

35.34

32.77

34.88

35.27

Interest

5.74

5.84

5.07

4.20

4.61

4.67

5.61

Exceptional Items

0.00

Gross Profit (PBDT)

44.05

34.12

37.16

31.14

28.16

30.21

29.66

Depreciation

10.02

9.75

8.64

8.70

8.62

8.38

7.92

Profit Before Tax

34.04

24.37

28.52

22.44

19.54

21.83

21.74

Tax

8.91

5.65

8.44

5.36

5.68

5.46

5.69

Provisions and contingencies

0.00

Profit After Tax

25.13

18.71

20.08

17.08

13.86

16.37

16.05

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

25.13

18.71

20.08

17.08

13.86

16.37

16.05

Share in Profit of Associates

0.18

1.78

0.23

1.16

0.24

0.10

1.23

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

25.31

20.49

20.32

18.24

14.10

16.48

17.28

Equity Capital

9.37

8.87

8.47

Face Value

1.0

Reserves

0.00

Earnings per share (EPS)

2.7

2.31

2.29

2.15

1.66

1.95

2.04

Diluted Earnings per share

2.84

2.31

2.4

2.15

1.67

1.95

2.04

Operating Profit Margin (Excl OI)

19.95%

20.08%

16.44%

19.16%

15.99%

20.38%

13.68%

Gross Profit Margin

18.17%

17.4%

14.97%

17.96%

14.31%

18.37%

12.07%

PAT Margin

10.37%

9.54%

8.09%

9.85%

7.04%

9.95%

6.53%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Sep 2025 is 23.66% vs -21.01% in Jun 2025

Consolidate Net Profit

QoQ Growth in quarter ended Sep 2025 is 23.52% vs 0.84% in Jun 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Sep 2025 is 22.83% vs -3.53% in Jun 2025

Interest

QoQ Growth in quarter ended Sep 2025 is -1.71% vs 15.19% in Jun 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

Compare Quarterly Results Of SMS Pharma. With

Select Peers

Figures in Cr

Consolidate Quarterly Results

Change(INR)

Change(%)

Net Sales

242.43

318.50

-76.07

-23.88%

Other Operating Income

0.00

Total Operating income

242.43

318.50

-76.07

-23.88%

Raw Material Cost

106.56

218.70

-112.14

-51.28%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

33.26

-92.40

125.66

136.00%

Employee Cost

19.25

69.60

-50.35

-72.34%

Power Cost

0.00

Manufacturing Expenses

25.74

0.00

25.74

Selling and Distribution Expenses

0.00

Other Expenses

9.26

115.40

-106.14

-91.98%

Total Expenditure (Excl Depreciation)

194.07

311.30

-117.23

-37.66%

Operating Profit (PBDIT) excl Other Income

48.36

7.20

41.16

571.67%

Other Income

1.43

1.90

-0.47

-24.74%

Operating Profit (PBDIT)

49.79

9.10

40.69

447.14%

Interest

5.74

14.90

-9.16

-61.48%

Exceptional Items

0.00

Gross Profit (PBDT)

44.05

-5.80

49.85

859.48%

Depreciation

10.02

41.20

-31.18

-75.68%

Profit Before Tax

34.04

-47.00

81.04

172.43%

Tax

8.91

-12.10

21.01

173.64%

Provisions and contingencies

0.00

Profit After Tax

25.13

-34.90

60.03

172.01%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

25.13

-34.90

60.03

172.01%

Share in Profit of Associates

0.18

0.00

0.18

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

25.31

-34.90

60.21

172.52%

Equity Capital

9.37

24.70

-15.33

-62.06%

Face Value

1.00

2.00

0.00

Reserves

0.00

Earnings per share (EPS)

2.70

-2.83

5.53

195.41%

Diluted Earnings per share

2.84

-2.83

5.67

200.35%

Operating Profit Margin (Excl OI)

19.95%

2.28%

0.00

17.67%

Gross Profit Margin

18.17%

-1.83%

0.00

20.00%

PAT Margin

10.37%

-11.04%

0.00

21.41%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 242.43 Cr

in Sep 2025

Figures in Cr

QoQ Growth in quarter ended Sep 2025 is 23.66% vs -21.01% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 23.22% vs 18.07% in Sep 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit 25.31 Cr

in Sep 2025

Figures in Cr

QoQ Growth in quarter ended Sep 2025 is 23.52% vs 0.84% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 79.50% vs 20.20% in Sep 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 48.36 Cr

in Sep 2025

Figures in Cr

QoQ Growth in quarter ended Sep 2025 is 22.83% vs -3.53% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 53.67% vs 13.12% in Sep 2024

Quarterly - Interest

Interest 5.74 Cr

in Sep 2025

Figures in Cr

QoQ Growth in quarter ended Sep 2025 is -1.71% vs 15.19% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 24.51% vs -17.24% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 19.95%

in Sep 2025

Figures in %

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024